CA2396351C - New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders - Google Patents
New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders Download PDFInfo
- Publication number
- CA2396351C CA2396351C CA002396351A CA2396351A CA2396351C CA 2396351 C CA2396351 C CA 2396351C CA 002396351 A CA002396351 A CA 002396351A CA 2396351 A CA2396351 A CA 2396351A CA 2396351 C CA2396351 C CA 2396351C
- Authority
- CA
- Canada
- Prior art keywords
- antipsychotic
- antipsychotic agent
- methyl
- indol
- dioxino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000028017 Psychotic disease Diseases 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 230000002265 prevention Effects 0.000 title abstract description 5
- 230000001225 therapeutic effect Effects 0.000 title abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000000164 antipsychotic agent Substances 0.000 claims description 34
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 31
- DYJIKHYBKVODAC-ZDUSSCGKSA-N (2s)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one Chemical compound C([C@H]1COC=2C=CC3=C(C=2O1)CC(N3)=O)NCC1=CC=CC=C1 DYJIKHYBKVODAC-ZDUSSCGKSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 19
- 229960003878 haloperidol Drugs 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 claims description 7
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 7
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 6
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 6
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 6
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims description 6
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical group C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 6
- 229960001076 chlorpromazine Drugs 0.000 claims description 6
- 229960004170 clozapine Drugs 0.000 claims description 6
- 229960002690 fluphenazine Drugs 0.000 claims description 6
- 229960000423 loxapine Drugs 0.000 claims description 6
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims description 6
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims description 6
- 229960000300 mesoridazine Drugs 0.000 claims description 6
- 229960004938 molindone Drugs 0.000 claims description 6
- 229960005017 olanzapine Drugs 0.000 claims description 6
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 6
- 229960000762 perphenazine Drugs 0.000 claims description 6
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 claims description 6
- 229960001534 risperidone Drugs 0.000 claims description 6
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 6
- 229940035004 seroquel Drugs 0.000 claims description 6
- 229960002784 thioridazine Drugs 0.000 claims description 6
- 229960005013 tiotixene Drugs 0.000 claims description 6
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 6
- 229960002324 trifluoperazine Drugs 0.000 claims description 6
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 5
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 208000022610 schizoaffective disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 7
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 30
- 208000024891 symptom Diseases 0.000 description 12
- 208000009132 Catalepsy Diseases 0.000 description 10
- 206010047853 Waxy flexibility Diseases 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 229960000632 dexamfetamine Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 229940005529 antipsychotics Drugs 0.000 description 5
- 208000012661 Dyskinesia Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- -1 (S)-2-(Benzyl-amino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one Chemical compound 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229950000688 phenothiazine Drugs 0.000 description 3
- 206010001540 Akathisia Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 230000035863 hyperlocomotion Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 description 1
- OARVASKAQZMJHP-UHFFFAOYSA-N 1-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]imidazolidin-2-one Chemical compound N=1OC2=CC(F)=CC=C2C=1C(CC1)CCN1CCN1CCNC1=O OARVASKAQZMJHP-UHFFFAOYSA-N 0.000 description 1
- HTSNFXAICLXZMA-CYBMUJFWSA-N 3-[(3s)-1-propylpiperidin-3-yl]phenol Chemical compound C1N(CCC)CCC[C@H]1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-CYBMUJFWSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
- BYYPZLZUDUJJTA-UHFFFAOYSA-N [1,4]dioxino[2,3-e]indol-8-one Chemical compound O1C=COC2=C1C=CC1=NC(=O)C=C21 BYYPZLZUDUJJTA-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001484 cataleptigenic effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940097480 cogentin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229950001815 preclamol Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229960004558 terguride Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45860799A | 1999-12-10 | 1999-12-10 | |
| US09/458,607 | 1999-12-10 | ||
| PCT/US2000/033060 WO2001041750A2 (en) | 1999-12-10 | 2000-12-07 | Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2396351A1 CA2396351A1 (en) | 2001-06-14 |
| CA2396351C true CA2396351C (en) | 2009-11-10 |
Family
ID=23821437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002396351A Expired - Lifetime CA2396351C (en) | 1999-12-10 | 2000-12-07 | New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1235570A2 (cs) |
| JP (1) | JP5557409B2 (cs) |
| KR (1) | KR100772854B1 (cs) |
| CN (1) | CN1230164C (cs) |
| AR (1) | AR026756A1 (cs) |
| AU (1) | AU784211B2 (cs) |
| BR (1) | BR0016168A (cs) |
| CA (1) | CA2396351C (cs) |
| CZ (1) | CZ20021880A3 (cs) |
| EA (1) | EA005002B1 (cs) |
| HK (1) | HK1045942A1 (cs) |
| HU (1) | HUP0203309A3 (cs) |
| IL (2) | IL149669A0 (cs) |
| MX (1) | MXPA02005649A (cs) |
| NO (1) | NO20022739D0 (cs) |
| NZ (1) | NZ519381A (cs) |
| PL (1) | PL355292A1 (cs) |
| TW (1) | TWI222864B (cs) |
| WO (1) | WO2001041750A2 (cs) |
| ZA (1) | ZA200205484B (cs) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2405404T3 (es) | 2003-10-29 | 2013-05-31 | Wyeth Llc | Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados |
| JP2008530229A (ja) | 2005-02-17 | 2008-08-07 | ワイス | シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体 |
| KR20100113163A (ko) * | 2008-02-13 | 2010-10-20 | 타가셉트 인코포레이티드 | 알파 ７ 니코틴 작용제 및 항정신병제의 조합 |
| RS63302B1 (sr) * | 2020-05-04 | 2022-07-29 | Bioprojet Pharma | Upotreba dopaminskih d3 delimičnih agonista za tretiranje poremećaja centralnog nervnog sistema |
| GB202014184D0 (en) | 2020-09-09 | 2020-10-21 | Johnson Matthey Plc | Modifed catalyst supports and catalysts supported thereon |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2987484B2 (ja) * | 1995-03-16 | 1999-12-06 | 大塚製薬 株式会社 | カルボスチリル誘導体の製造方法 |
| US5756532A (en) * | 1995-11-06 | 1998-05-26 | American Home Products Corporation | Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives |
| GB9627005D0 (en) * | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
-
2000
- 2000-12-07 CA CA002396351A patent/CA2396351C/en not_active Expired - Lifetime
- 2000-12-07 CZ CZ20021880A patent/CZ20021880A3/cs unknown
- 2000-12-07 IL IL14966900A patent/IL149669A0/xx active IP Right Grant
- 2000-12-07 EP EP00982461A patent/EP1235570A2/en not_active Withdrawn
- 2000-12-07 EA EA200200656A patent/EA005002B1/ru not_active IP Right Cessation
- 2000-12-07 AU AU19490/01A patent/AU784211B2/en not_active Ceased
- 2000-12-07 BR BR0016168-3A patent/BR0016168A/pt not_active Application Discontinuation
- 2000-12-07 CN CNB008169527A patent/CN1230164C/zh not_active Expired - Lifetime
- 2000-12-07 WO PCT/US2000/033060 patent/WO2001041750A2/en not_active Ceased
- 2000-12-07 PL PL00355292A patent/PL355292A1/xx not_active Application Discontinuation
- 2000-12-07 HK HK02107378.5A patent/HK1045942A1/zh unknown
- 2000-12-07 KR KR1020027007286A patent/KR100772854B1/ko not_active Expired - Fee Related
- 2000-12-07 HU HU0203309A patent/HUP0203309A3/hu unknown
- 2000-12-07 MX MXPA02005649A patent/MXPA02005649A/es active IP Right Grant
- 2000-12-07 NZ NZ519381A patent/NZ519381A/en unknown
- 2000-12-07 JP JP2001543095A patent/JP5557409B2/ja not_active Expired - Lifetime
- 2000-12-07 AR ARP000106504A patent/AR026756A1/es unknown
- 2000-12-08 TW TW089126071A patent/TWI222864B/zh not_active IP Right Cessation
-
2002
- 2002-05-15 IL IL149669A patent/IL149669A/en not_active IP Right Cessation
- 2002-06-07 NO NO20022739A patent/NO20022739D0/no not_active Application Discontinuation
- 2002-07-09 ZA ZA200205484A patent/ZA200205484B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1230164C (zh) | 2005-12-07 |
| CZ20021880A3 (cs) | 2002-08-14 |
| PL355292A1 (en) | 2004-04-05 |
| JP2003516350A (ja) | 2003-05-13 |
| CN1409633A (zh) | 2003-04-09 |
| KR20030016207A (ko) | 2003-02-26 |
| WO2001041750A2 (en) | 2001-06-14 |
| CA2396351A1 (en) | 2001-06-14 |
| AU784211B2 (en) | 2006-02-23 |
| JP5557409B2 (ja) | 2014-07-23 |
| EA200200656A1 (ru) | 2002-12-26 |
| NO20022739L (no) | 2002-06-07 |
| HUP0203309A3 (en) | 2004-12-28 |
| ZA200205484B (en) | 2003-12-31 |
| TWI222864B (en) | 2004-11-01 |
| IL149669A0 (en) | 2002-11-10 |
| NZ519381A (en) | 2004-04-30 |
| MXPA02005649A (es) | 2004-09-10 |
| AU1949001A (en) | 2001-06-18 |
| AR026756A1 (es) | 2003-02-26 |
| HK1045942A1 (zh) | 2002-12-20 |
| IL149669A (en) | 2006-06-11 |
| EA005002B1 (ru) | 2004-10-28 |
| KR100772854B1 (ko) | 2007-11-02 |
| EP1235570A2 (en) | 2002-09-04 |
| HUP0203309A2 (hu) | 2003-01-28 |
| WO2001041750A3 (en) | 2002-02-14 |
| BR0016168A (pt) | 2002-08-20 |
| NO20022739D0 (no) | 2002-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1994932A1 (en) | Use of N-desmethylclozapine to treat human psychosis | |
| JP2007516275A (ja) | 認知増強および精神病性障害のための治療的組合せ | |
| US20090258084A1 (en) | Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia | |
| US20090306040A1 (en) | Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia | |
| CA2601509A1 (en) | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions | |
| US20070238725A1 (en) | Therapeutic combinations for the treatment or prevention of psychotic disorders | |
| CA2396351C (en) | New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders | |
| US6350773B1 (en) | Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders | |
| AU2004246820B2 (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
| CA2649590A1 (en) | Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome | |
| Cheng et al. | Dopamine hypothesis | |
| MXPA05013580A (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20201207 |